TY - JOUR
T1 - Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose
T2 - FAIR-HF sub-analysis
AU - Gutzwiller, Florian S.
AU - Pfeil, Alena M.
AU - Comin-Colet, Josep
AU - Ponikowski, Piotr
AU - Filippatos, Gerasimos
AU - Mori, Claudio
AU - Braunhofer, Peter G.
AU - Szucs, Thomas D.
AU - Schwenkglenks, Matthias
AU - Anker, Stefan D.
PY - 2013/10/9
Y1 - 2013/10/9
N2 - Background Heart failure (HF) is a burden to patients and health care systems. The objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce mortality and morbidity. We aimed to evaluate determinants of health-related quality of life (HRQoL) in patients with iron deficiency and HF treated with intravenous (i.v.) iron substitution or placebo. Methods A randomised, double-blind, placebo-controlled trial (n = 459) in iron-deficient chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL benefits of i.v. iron substitution using ferric carboxymaltose (FCM) over a 24-week trial period. Multivariate analysis was carried out with various clinical variables as independent variables and HRQoL measures as dependent variables. Results Mean change from baseline of European Quality of Life - 5 Dimensions (EQ-5D) (value set-based) utilities (on a 0 to 100 scale) at week 24 was 8.91 (i.v. iron) and 0.68 (placebo; p <0.01). In a multivariate analysis excluding baseline HRQoL, a higher exercise tolerance and i.v. iron substitution positively influenced HRQoL, whereas impaired renal function and a history of stroke had a negative effect. The level of HRQoL was also influenced by country of residence. When baseline HRQoL was factored in, the multivariate model remained stable. Conclusion In this study, i.v. iron substitution, exercise tolerance, stroke, country of residence and renal function influenced measures of HRQoL in patients with heart failure and iron deficiency.
AB - Background Heart failure (HF) is a burden to patients and health care systems. The objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce mortality and morbidity. We aimed to evaluate determinants of health-related quality of life (HRQoL) in patients with iron deficiency and HF treated with intravenous (i.v.) iron substitution or placebo. Methods A randomised, double-blind, placebo-controlled trial (n = 459) in iron-deficient chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL benefits of i.v. iron substitution using ferric carboxymaltose (FCM) over a 24-week trial period. Multivariate analysis was carried out with various clinical variables as independent variables and HRQoL measures as dependent variables. Results Mean change from baseline of European Quality of Life - 5 Dimensions (EQ-5D) (value set-based) utilities (on a 0 to 100 scale) at week 24 was 8.91 (i.v. iron) and 0.68 (placebo; p <0.01). In a multivariate analysis excluding baseline HRQoL, a higher exercise tolerance and i.v. iron substitution positively influenced HRQoL, whereas impaired renal function and a history of stroke had a negative effect. The level of HRQoL was also influenced by country of residence. When baseline HRQoL was factored in, the multivariate model remained stable. Conclusion In this study, i.v. iron substitution, exercise tolerance, stroke, country of residence and renal function influenced measures of HRQoL in patients with heart failure and iron deficiency.
KW - Anaemia
KW - Ferric carboxymaltose
KW - Heart failure
KW - Iron deficiency
KW - Multivariate analysis
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84886246232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886246232&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2013.06.045
DO - 10.1016/j.ijcard.2013.06.045
M3 - Article
C2 - 23870642
AN - SCOPUS:84886246232
VL - 168
SP - 3878
EP - 3883
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 4
ER -